Medacta Group (FRA:6MD) Beta: 0.4388 (As of Jun. 25, 2026)


FRA:6MD Medacta Group SA FRA:6MD
91 GF Score
Price €143.00
GF Value €178.79
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group Beta?

Medacta Group FRA:6MD +1.42% 91 Beta is 0.4388 as of Jun. 25, 2026. GuruFocus rates FRA:6MD with a GF Score™ of 91/100 and a GF Value™ of €178.79 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Medacta Group's Beta is 0.4388.


Medacta Group  (FRA:6MD) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Medacta Group Beta Related Terms


Medacta Group Beta Historical Data

* Premium members only.

The historical data trend for Medacta Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group Beta Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.01 -0.01 -0.41

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 0.20 -0.41

FRA:6MD vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, Medacta Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medacta Group Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Beta distribution charts can be found below:

* The bar in red indicates where Medacta Group's Beta falls into.


FRA:6MD
91GF Score
Medacta Group SA FRA:6MD
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4388 mean?
Medacta Group (FRA:6MD) has a Beta of 0.4388 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medacta Group and its competitors.
Is Medacta Group's Beta too high?
Medacta Group's current Beta is 0.4388. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Beta compare to ABT and SYK?
Medacta Group's Beta of 0.4388 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medacta Group and its competitors. Medacta Group's current Beta is 0.4388. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €178.79, compared to a current price of €143.00 — trading 20% below its estimated fair value. The current Beta is 0.4388. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current Beta is 0.4388 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (FRA:6MD) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of €143.00 is trading 20% below its estimated GF Value™ of €178.79. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for FRA:6MD:

  • Beta: 0.4388
  • GF Value™: €178.79 vs. price of €143.00 (20% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score

Get the complete analysis for FRA:6MD

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.00
Price
€178.79
GF Value